Market Overview:
The global hemoglobinopathies market reached a value of US$ 8.36 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 14.8 Billion by 2027 exhibiting a CAGR of 9.50% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Hemoglobinopathies is genetic blood disorder that causes structural and production abnormalities in hemoglobin molecules. Sickle cell, thalassemia, hemoglobin C, and beta-thalassemia are some of the common types of hemoglobinopathies. Hemoglobinopathies are detected by genetic testing, hemoglobin by high-performance liquid chromatography, routine red blood cell (RBC) count, hemoglobin isoelectric focusing (Hb IEF), and hemoglobin electrophoresis (Hb ELP) test. Pale skin, shortness of breath, cold hands or feet, tiredness, pain, and swelling in the hands and feet are a few of the most common symptoms hemoglobinopathies. Some of the widely used hemoglobinopathies treatment solutions include antibiotics, ACE inhibitors, stem-cell transplantation, blood transfusions, hydroxyurea, and analgesic.
www.imarcgroup.com
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
Hemoglobinopathies Market Trends:
The increasing prevalence of various medical conditions, such as sickle cell disease (SCD) and thalassemia, is one of the key factors driving the growth of the market. Hemoglobinopathies are caused by abnormal hemoglobin that deforms and damages red blood cells and makes them hard and sticky. In line with this, the rising prevalence of anemia, especially among the geriatric population, which is also susceptible to various other chronic ailments, is favoring the market growth. Various technological advancements, such as the development of CRISPR-Cas9 technology to cure hemoglobinopathies by editing, removing, adding, or altering genes and modifying the DNA, are providing an impetus to the market growth. In line with this, the widespread adoption of gene therapy for the treatment of hemoglobinopathy is favoring market growth. Other factors, such as the significant expansion in the healthcare industry, along with the implementation of various government initiatives to promote research and development (R&D) activities to introduce novel therapies for treating hemoglobinopathies at affordable costs is anticipated to provide a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hemoglobinopathies market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, treatment, test type and end user.
Breakup by Type:
- Thalassemia
- Alpha Thalassemia
- Beta Thalassemia
- Sickle Cell Disease
- Others
Breakup by Treatment:
www.imarcgroup.com
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
- Blood Transfusion
- Stem-cell Transplantation
- Analgesics
- Antibiotics
- ACE Inhibitors
- Hydroxyurea
- Others
Breakup by Test Type:
- Red Blood Cell (RBC) Count
- Genetic Testing
- High Performance Liquid Chromatography (HPLC)
- Hemoglobin Isoelectric Focusing (Hb IEF)
- Hemoglobin Electrophoresis (Hb ELP)
- Hemoglobin Solubility Test
Breakup by End User:
- Hospitals and Clinics
- Diagnostics Laboratories
- Others
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Bio-Rad Laboratories Inc., bluebird bio Inc., Bristol-Myers Squibb Company, Danaher Corporation, Emmaus Life Sciences Inc., Gamida-Cell Ltd., Global Blood Therapeutics Inc., Novartis AG, PerkinElmer Inc., Pfizer Inc., Prolong Pharmaceuticals LLC, Sangamo Therapeutics Inc. and Sysmex Corporation.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2021 |
Historical Period |
2016-2021 |
Forecast Period |
2022-2027 |
Units |
US$ Billion |
Segment Coverage |
Type, Treatment, Test Type, End User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Bio-Rad Laboratories Inc., bluebird bio Inc., Bristol-Myers Squibb Company, Danaher Corporation, Emmaus Life Sciences Inc., Gamida-Cell Ltd., Global Blood Therapeutics Inc., Novartis AG, PerkinElmer Inc., Pfizer Inc., Prolong Pharmaceuticals LLC, Sangamo Therapeutics Inc. and Sysmex Corporation. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |